NCI-2023-03181: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 23, 2026 - P1/2 | N=50 | Suspended | Sponsor: City of Hope Medical Center | Recruiting ➔ Suspended
Trial suspension • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CCND1 • CDKN2A • KMT2D • NOTCH2 • NSD2 • SOX11 • TP53
|